We have compared the antagonism of neuromuscular block produced by pipecuronium with pancuronium in 80 anaesthetized surgical patients using mechanomyography and electromyography. Pancuronium 0.1 mg kg" 1 or pipecuronium 0.07 mg kg -1 was given after induction of anaesthesia and neuromuscular block was adjusted to 75% twitch depression at the time of antagonism. The following regimens were used: edrophonium 0.5 and 1.0 mg kg" 1 , neostigmine 0.04 mg kg" 1 , pyridostigmine 0.3 mg kg" 1 and edrophonium 0.25 mg kg" 1 with pyridostigmine 0.15 mg kg"
With the introduction of new, non-depolarizing neuromuscular blocking agents and the availability of different reversal agents (e.g. neostigmine, edrophonium and pyridostigmine), the pharmacological scope for antagonism of neuromuscular block is broadening. Variations in the degree of clinical reversibility among different neuromuscular blockers was documented some time ago [1] , but it has also been the subject of recent studies. For example, variations in the degree of antagonism of the same blocker by different reversal agents (in the presence of different anaesthetics) have been reported. Pharmacodynamic differences among various reversal agents have also been recognized, both in clinical and in earlier animal studies [2, 3] .
The main objective of this study was to compare antagonism of neuromuscular block produced by pancuronium or pipecuronium.
Patients and methods
Eighty surgical patients, aged 18-60 yr, ASA I-II, with no significant neuromuscular, musculoskeletal, cardiac, renal, hepatic or pulmonary diseases, were enrolled in the study which was approved by our Ethics Committee. Written, informed consent was obtained from all patients. Randomization within treatment groups was by tables of random numbers.
Patients received morphine 0.15 mg kg-' i.m. or diazepam 0.04 kg i.v. or 0.15 mg kg" 1 orally before anaesthesia. Anaesthesia was induced with thiopentone 4-5 mg kg" 1 i.v. and maintained with 1.0-1.2% halothane and 66% nitrous oxide in oxygen. The concentration of halothane was adjusted subsequently to 0.5-0.8 % (end-tidal). When necessary, small doses of fentanyl (e.g. l.Ougkg-') were given i.v. to supplement anaesthesia. End-tidal halothane concentration was measured by a Datex Model 222 anaesthesia vapour analyser. Oesophageal temperature was maintained at 35-37 °C with the use of a heating pad.
Pancuronium 0.1 mg kg" 1 or pipecuronium 0.07 mg kg-' was given as a single i.v. dose in the right forearm after induction of anaesthesia, before oral tracheal intubation. Neuromuscular responses were monitored electromyographically (EMG) and mechanomyographically (MMG) in the following way: EMG and MMG train-of-four (TOF) responses were recorded on the left arm and mechanical responses on the right arm. The MMG responses were obtained through two force transducers (Harvard Apparatus Co. Model 52-9530, Dover, MA, USA) attached to each thumb, applying 100-150 g of resting tension, and recorded on a chart recorder. Each arm was attached to an arm board and covered, except for the thumb, to prevent excessive bolus doses were given to adjust the degree of neuromuscular block to 75 % at the time of antagonism. The infusion was continued until the reversal agent was given and, in cases of bolus dose administration, the reversal agent was given when recovery from the last bolus dose of the blocker reached 75% block of the Tl response.
One of the following regimens was used: edrophonium 0.5 and 1.0 mg kg" . The time of administration of each agent was chosen in relation to the estimated completion of surgery and speed of onset of the reversal agent. Thus edrophonium was given approximately 5 min before termination of surgery and pyridostigmine 15-20 min before completion of surgery in order to minimize duration of stay in the operating room. Each reversal regimen was given to a group of eight patients paralysed with pipecuronium and a group of eight patients paralysed with pancuronium while still anaesthetized with 0.5-0.7% end-tidal halothane. Glycopyrronium 0.007 mg kg-' was administered 2 min before each reversal agent.
Antagonism was evaluated at 2, 5, 10 and 15 min after administration of the reversal drugs. Controlled ventilation continued during the reversal process and was converted to assisted ventilation when indicated. The following variables were determined: onset time of antagonism (time of completing injection to peak antagonism of neuromuscular block); and degree of antagonism of the MMG twitch response, TOF (T4/T1 ratios of MMG and EMG responses) and tetanic fade. In the postanaesthesia care unit (PACU) the efficacy of the reversal agents was assessed by the head-lift test; the patient was requested to hold the head up from the supine position for 5 s. This test was performed on arrival in the PACU (20-25 min after antagonism) and 30 min later. Patients who were not easily rousable were excluded from this evaluation.
Mean (SEM) values were calculated for the measured responses of antagonism of neuromuscular block. Clinically relevant reversal data points (i.e. magnitude of the twitch response and TOF fade ratios, 15 min after antagonism) were compared. Data on antagonism of tetanic fade were not compared statistically. As the primary aim was to compare differences between the reversal regimens, comparisons of the reversal regimen and blocker groups were not made. When applicable, one-way ANOVA followed by contrasts was used for comparing the reversing efficacy of edrophonium and pyridostigmine with that of their combination. Differences between groups were compared by Student's t test. In the case of quantal responses (e.g. head lift), differences were analysed by Fisher's exact test. Statistical significance was denned as P < 0.05.
Results
Patient characteristics are shown in table 1 and the results of antagonism of neuromuscular block in tables 2-5. Antagonism of the Tl response and TOF fade with edrophonium was initially rapid, reaching a near-maximum (e.g. 75-90%) level within 2 min. Full antagonism was reached within 5-10 min. In contrast with Tl antagonism, TOF fade antagonism was incomplete with edrophonium 0.5 mg kg" 1 and less than optimal (e.g. 0.7) throughout the 15-min observation period after edrophonium l.Omgkg-'. The maximum TOF ratios after edrophonium 0.5 and 1.0 mg were 0.65 MMG and 0.76 EMG, respectively, when antagonizing pipecuronium-induced neuromuscular block, and 0.63 MMG and 0.67 EMG, respectively, when antagonizing pancuronium. The time pattern for antagonism was similar with pipecuronium and pancuronium. Maximum degrees of antagonism of tetanic fade (tables 4, which had not reached a maximum level in 10 min. In the case of the twitch response, there was an overshoot. The peak Tl response at 15 min into the antagonism was 23% greater with pipecuronium compared with control. With pancuronium the peak Tl response after antagonism was only 3% greater. T4/T1 ratios reached 0.7 or higher after only 15 min. This occurred with both blockers and for both EMG and MMG responses. Degrees of antagonism of tetanic fade ranged between 47 % and 90 % during the reversal period, and at 15 min reached 83 % (pancuronium) and 90 % (pipecuronium).
The reversing effect of neostigmine was slower (5-8 min) than edrophonium (1.5-2.5 min). The twitch response was antagonized fully by 10-15 min. TOF fade response antagonism was adequate with both blockers but only at 15 min after antagonism. The TOF fade ratios were slightly, but insignificantly, lower with pipecuronium than with pancuronium. No differences between the EMG and MMG responses were noted. Maximum degrees of reversal of tetanic fade (tables 4 and 5) ranged between 39 % and 96 % during the reversal period, and at the end (at 15 min) had reached 83% (pipecuronium) and 96 % (pancuronium).
The combination of pyridostigmine 0.15 mg kg" 1 and edrophonium 0.25 mg kg" 1 (tables 2, 3) produced a reversal pattern which was faster than pyridostigmine alone (P ^ 0.05) but somewhat (although not significantly) slower than edrophonium alone. At 15 min after antagonism, this combination produced no more complete antag- (11) 73 (11) 79 (11) 5(2.5) 48 (12) 55 (12) 58 (12) 59 (12) 0 47 (15) 76 (11) 82 (10) 82 (10) 2(1.6) 53(17) 87 (6) 93 (3) 96 (2.5) 0 79 (11) 72 (11) 72 (11) 77(11) onism of TOF fade than did edrophonium 0.5 mg kg" 1 alone. The potency of the combination in antagonizing TOF fade was inferior to that of pyridostigmine in the case of pancuronium (P ^ 0.02). With this reversing regimen, maximum antagonism of tetanic fade ranged between 69% and 89% during the reversal period and, at 15 min, had reached 89% (pipecuronium) and 77% (pancuronium).
We also assessed the efficacy of TOF fade antagonism by comparing the percentage of patients per treatment group which developed, within 15 min, TOF fade ratios > 0.7 (table 6) . Based on these data, the following rank order of reversing potency was obtained: pancuronium: pyridostigmine ñ eostigmine > edrophonium 1.0 mg > edrophonium + pyridostigmine > edrophonium 0.5 mg; and pipecuronium: pyridostigmine > neostigmine > edrophonium + pyridostigmine > edrophonium 1.0 mg > edrophonium 0.5 mg. Table 7 shows the data obtained with the head lift test during the first 30 min in the PACU. The majority of patients showed positive responses in all reversal groups. There were fewer positive responses in the edrophonium groups but this was not statistically significant.
Discussion
Although the doses of the reversal agents were selected on the basis of previously determined [2] potency, we found minor differences in the efficacy of action of different reversal regimens. The difference may be explained by the fact that the potency data were based on antagonism of tubocurarine and 50 % twitch response. Data on antagonism of tetanic fade should be considered as semi-quantitative only for several reasons. The variability of the degree of tetanic fade is usually quite high and, even with careful immobilization of the arm and assuring constant preload on the thumb, baseline shifts can occur. The blood pressure cuff attached to the arm may have affected the distribution of the reversal agents. Finally, during antagonism, tetanic stimuli were applied 2-5 min apart; this is more frequent than considered optimal, as post-tetanic potentiation or exhaustion may both occur when the responses are produced more frequently than every 7-10 min. Nevertheless, the trend of the reversal of tetanic fade corresponded reasonably well with data obtained for recovery of the twitch response and TOF fade. At 15 min into the reversal process, antagonism of tetanic fade, based on the means of the pipecuronium and pancuronium groups, showed the following rank order: neostigmine (89%) > pyridostigmine (83 %) > edrophonium + pyridostigmine (80 %) > edrophonium 1.0 mg/kg > (68 %) > edrophonium 0.5mg/kg(66%).
The differences in the onset of action of reversal regimens for pipecuronium-and pancuroniuminduced neuromuscular block correspond with reversal of block produced by other agents. The reversibility of neuromuscular block elicited by pipecuronium and pancuronium was generally similar. This can be explained by the very similar chemical structure and similar pharmacokinetic features of these two neuromuscular blockers [4] . An overshoot in the reversal of the twitch response which occurred only with pyridostigmine-induced reversal of pipecuronium block remains unexplained.
Block of "tonic" responses (e.g. first twitch of the TOF) is attributed to a postjunctional effect, while the fade responses are considered to be prejunctional [5, 6] . Neuromuscular blockers in common use are known to act at both pre-but mostly postjunctional sites [7] [8] [9] [10] . An early study compared the clinical reversal of different non-depolarizing blockers by neostigmine, and found significant differences in the reversibility of their twitch responses. The following order of reversibility was established: tubocurarine > pancuronium > gallamine [1] . Non-depolarizing neuromuscular blocking agents differ also as to the degrees of recovery of their TOF fade after neostigmine antagonism [11] . In this study we found no differences between the reversibility of pipecuronium-and pancuronium-induced neuromuscular block.
The role of pre-and postjunctional components in the action of reversal agents was evaluated by Donati, Ferguson and Bevan [2] . They suggested that edrophonium antagonizes prejunctional block preferentially and pyridostigmine antagonizes postjunctional block primarily. According to this concept, edrophonium would be a more appropriate antagonist than pyridostigmine against the marked fade response produced by pancuronium. In contrast, we found that edrophonium was less potent than either neostigmine or pyridostigmine in antagonizing TOF fade and tetanic fade than the twitch response. Combining two reversal agents, with supposedly different pre-and postjunctional sites of action, was suggested also to have a synergistic effect [2] . However, no synergistic effect between edrophonium and pyridostigmine has been found [12, 13] . Similarly, in the present study the combination of edrophonium and pyridostigmine did not result in any synergism. The onset of action of the combination was closer to that of edrophonium alone than that of pyridostigmine above. The potency of the combination was identical to that of edrophonium and slightly inferior to that of pyridostigmine. Furthermore, in another study, the combination of edrophonium and neostigmine did not result in a reversal regimen of enhanced potency [14] .
In conclusion, because of its lower efficacy and relatively short lasting presynaptic reversal characteristics, edrophonium should be the last choice in the antagonism of neuromuscular block produced by pancuronium and pipecuronium.
